Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jazz/Solvay Gain Approval Of Luvox CR

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval of anxiety/obsessive compulsive disorder drug comes a day ahead of its scheduled user fee date.

You may also be interested in...



Jazz Delays Trials, Reduces Staff

Late-stage trials wait until 2009 as firm "leans in partnering direction," chairman tells "The Pink Sheet" DAILY.

Jazz Delays Trials, Reduces Staff

Late-stage trials wait until 2009 as firm "leans in partnering direction," chairman tells "The Pink Sheet" DAILY.

Jazz Pharmaceuticals’ Luvox CR Gets Feb. 29 Action Date

Company expects to launch the extended-release anti-anxiety medication in the first quarter, after FDA accepts response to “approvable” letter.

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel